• Dinaciclib Selectivity in VHL-Deficient Renal Cancer

  2026-09-08

  Nelson and colleagues identify a preclinical synthetic-lethal relationship between Dinaciclib treatment and VHL deficiency in clear cell renal cell carcinoma. Their combination of cell-based assays, pathway analysis, VHL re-expression, and an orthotopic patient-derived xenograft model supports selective targeting of both tumor cells and CD105-defined cancer stem-cell populations, while also highlighting important translational limitations.

• Purmorphamine: Smoothened Agonist Workflows

  2026-09-08

  Purmorphamine is a practical Smoothened agonist for connecting Hedgehog pathway activation with osteogenic, receptor-level, and sensory readouts. This guide translates product specifications and honeybee Smo findings into dose-aware workflows, controls, and troubleshooting strategies for bone regeneration research and beyond.

• Self-Assembling EVMPs for Extrahepatic mRNA Delivery

  2026-09-07

  Yu and colleagues developed a bottom-up enveloped virus-mimicking particle (EVMP) that combines a self-assembling virus-mimicking peptide with programmable phospholipid envelopes for extrahepatic mRNA delivery. The platform achieved substantial lung-cell transfection and produced antitumor activity when loaded with IL-12 mRNA, while its modular design addresses important limitations of viral vectors and conventional liver-biased nanoparticles.

• Pyridostigmine Targets Placental Necroptosis in PE

  2026-09-07

  The reference study identifies placental necroptosis as a pharmacologically tractable component of preeclampsia-like pathology in rats. Its experiments link pyridostigmine-enhanced non-neuronal cholinergic signaling to α7 nicotinic acetylcholine receptor activity, reduced inflammation and oxidative stress, and improved trophoblast behavior.

• Nullscript: Translational Logic for HDAC Inhibition

  2026-09-05

  Nullscript offers a useful way to separate HDAC inhibition from transcriptional facilitation in translational research. This article connects its cardiac ischemia/reperfusion evidence with the mechanistic discipline demonstrated by recent RIPK3-necroptosis research, while defining practical limits for cardiovascular, neurodegeneration, and oncology studies.

• Bacterial HTS for Pharmacological Chaperones in AKU

  2026-09-04

  A 2025 European Journal of Pharmacology study developed a bacterial high-throughput assay to identify compounds that restore activity to missense variants of human homogentisate 1,2-dioxygenase in alkaptonuria. Screening 2,320 approved drugs produced 30 hits for the HGDG161R variant, while docking and dose-response data prioritized one compound for further investigation.

• Apicidin: HDAC Mechanism to Translational Strategy

  2026-09-04

  Apicidin is a selective histone deacetylase inhibitor whose value extends from cancer biology and angiogenesis research to emerging reproductive toxicology. This thought-leadership analysis connects HDAC3/HDAC6 pharmacology with assay design, translational decision-making, and the limits of interpreting preclinical efficacy.

• Phosphatase Inhibitor Cocktail 3: Reliable Workflows

  2026-09-03

  This scenario-based guide explains how Phosphatase Inhibitor Cocktail 3 (100X in DMSO), SKU K1014, helps preserve phosphorylation during lysate preparation associated with viability, proliferation, and cytotoxicity studies. It covers compatibility, dilution, storage, interpretation, and practical vendor-selection criteria for more defensible phosphoprotein analysis.

• SGI-1027 Triggers Apoptosis in Huh7 Cells

  2026-09-03

  The 2018 reference study showed that SGI-1027 reduced Huh7 hepatocellular carcinoma cell viability and induced apoptosis without significantly redistributing cells across cell-cycle phases. Its combination of viability testing, flow cytometry, TUNEL microscopy, and BCL-2/BAX immunoblotting supports a mitochondrial apoptosis model while also defining important limits on what the study directly demonstrated.

• Self-Amplifying RNA Influenza Vaccines: Dose Sparing

  2026-09-02

  The reference study compares nucleoside-modified mRNA, self-amplifying RNA, and circular RNA approaches for seasonal influenza vaccination, with particular attention to the weak immunogenicity of influenza B constructs. Its central finding is that self-amplifying RNA can improve low-dose antibody responses, protection, and durability in mice, while also clarifying the strain-specific limits of conventional mRNA designs.

• Caffeine Workflows for Cancer and Metabolic Research

  2026-09-02

  Build reproducible Caffeine assays for cancer cell line inhibition, metabolic phenotyping, and combination studies with valproic acid. A molecular simulation-guided cardiovascular study adds a useful framework for solubility-aware controls and orthogonal validation without overstating Caffeine’s mechanism.

• Recombinant Human Oncostatin M: Assay Workflows

  2026-09-01

  Build reproducible proliferation and cytokine-release assays with a tag-free, lyophilized rh-Oncostatin M preparation. This guide connects established OSM-responsive cell models with a carefully bounded, exploratory workflow for astrocyte and neuroinflammation research.

• Candida krusei Phases Trigger Distinct BMEC Apoptosis

  2026-09-01

  A 2023 study shows that the yeast and hypha phases of Candida krusei both induce apoptosis in bovine mammary epithelial cells, but through different dominant signaling routes. Its phase-resolved co-culture design links yeast-associated injury to mitochondrial dysfunction and hypha-associated injury to death ligand/receptor signaling, with TLR2/ERK and JNK/ERK pathways contributing to the response.

• ASCH Proteins and N4-Acetylcytidine Processing

  2026-08-31

  The 2025 Structure study clarifies how the E. coli ASCH-domain protein EcYqfB hydrolyzes free N4-acetylcytidine without acting as an RNA ac4C eraser. By combining crystal structures, cellular deletion experiments, and comparative analysis of homologous proteins, the work separates nucleoside metabolism from post-transcriptional RNA modification and identifies distinct substrate-recognition features across the ASCH family.

• Cy5 amine (non-sulfonated): Workflow Guide

  2026-08-31

  Cy5 amine (non-sulfonated) provides a primary amino group for covalent attachment of a bright red/far-red fluorophore to activated biomolecule substrates. It is intended for organic-solvent or mixed-solvent labeling workflows, not direct dissolution in water, long-term storage as a solution, or diagnostic and medical use.

8150 records 4/544 page Previous Next 12345 下5页 Last page